BioCentury
ARTICLE | Clinical News

Zalviso sufentanil: Phase III started

October 3, 2016 7:00 AM UTC

AcelRx began the open-label, U.S. Phase III IAP312 trial to evaluate 15 ug sublingual Zalviso sufentanil self-administered no more than once every 20 minutes for 24-72 hours after surgery in about 315...